View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 4, 2016

BioPharmX gets Health Canada approval to study Violet iodine to treat fibrocystic

US-based specialty pharmaceutical company BioPharmX has received approval from Health Canada to undertake phase 4 study of its Violet molecular iodine supplement for treatment of fibrocystic breast condition (FBC) and cyclic mastalgia.

US-based specialty pharmaceutical company BioPharmX has received approval from Health Canada to undertake phase 4 study of its Violet molecular iodine supplement for treatment of fibrocystic breast condition (FBC) and cyclic mastalgia.

Last month, the company that develops products for use in dermatology and women’s health received US FDA approval from to perform the study in the US.

To conduct the study, BioPharmX has selected KGK Synergize, an Ontario, Canada-based clinical research organisation focused on nutraceutical, biotechnology and pharmaceutical product research.

"The goal of this study is to learn more about the safety and potential benefits of molecular iodine to expand claims and support commercialisation of Violet iodine in international markets."

Under the randomised, double-blind, placebo-controlled and multi-centre study, the safety, tolerability and potential benefits of the molecular iodine dietary supplement, Violet, on breast health in women with cyclic breast pain and tenderness, will be assessed.

Results from the study are expected by the end of this year.

BioPharmX clinical and regulatory affairs executive vice president AnnaMarie Daniels said: "At least 875 million reproductive-age women around the world suffer from breast pain and discomfort due to fibrocystic breast condition.

"Previous studies have shown that molecular iodine results in a significant reduction in the symptoms of FBC.

"The goal of this study is to learn more about the safety and potential benefits of molecular iodine to expand claims and support commercialisation of Violet iodine in international markets, where the number of women with this condition is expected to grow to over a billion by 2050."

Last month, the company had obtained institutional review board (IRB) approval to begin a phase 4 study of Violet molecular iodine supplement.

The sample size for this study is expected to cover 120 females, with around 80 subjects receiving Violet iodine and around 40 subjects receiving the placebo in a double-blind manner.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena